<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml">
   <article xmlns="" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
      <head>
         <style type="text/css"> 		 
            	    table {background : #ffffdd;}
            		 	tr {background : #ddddff; padding : 1px;}
            			
         </style>
         <span class="citation_publisher">Hindawi Publishing Corporation</span>
         <h2 class="citation-title">Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and
            Antithyroperoxidase Antibodies
         </h2>
         <span class="doi">10.1155/2016/7402469</span>
         <div class="contrib-group">contrib: 
            	  CONT
            	  
            <span class="citation_author">Nadia Sawicka-Gutaj</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Ariadna Zybek-Kocik</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Aleksandra Klimowicz</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Michał Kloska</span>
            <span class="citation_author_institution_ref">2</span>
            <span class="citation_author">Dorota Mańkowska-Wierzbicka</span>
            <span class="citation_author_institution_ref">2</span>
            <span class="citation_author">Jerzy Sowiński</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Marek Ruchała</span>
            <span class="citation_author_institution_ref">1</span>
         </div>
         <span class="email">[nyha@o2.pl]</span>
         <span class="conflict">[]</span>
         <span class="contribs">[]</span>
         <span class="citation_pubdate">[2016-1-17]</span>
         <span class="citation_copyright">[Copyright 2016: ]</span>
         <span class="citation_licence">[Licence This is an open access article distributed under the Creative Commons Attribution
            License, which permits unrestricted use, distribution, and reproduction in any medium,
            provided the original work is properly cited.]
         </span>
         <span class="citation_funding">[]</span>
         <span class="citation_pagecount">[]</span>
         <span class="citation_data">[]</span>
      </head>
      <div id="abstract" tag="abstract">
         <h2>Abstract</h2>
         <p>We hypothesized that regulation of visfatin in hypothyroidism might be altered by
            coexisting chronic autoimmune thyroiditis. This is a prospective case-control study
            of 118 subjects. The autoimmune study group (AIT) consisted of 39 patients newly diagnosed
            with hypothyroidism in a course of chronic autoimmune thyroiditis. The nonautoimmune
            study group (TT) consisted of 40 patients thyroidectomized due to the differentiated
            thyroid cancer staged pT1. The control group comprised 39 healthy volunteers adjusted
            for age, sex, and BMI with normal thyroid function and negative thyroid antibodies.
            Exclusion criteria consisted of other autoimmune diseases, active neoplastic disease,
            diabetes mellitus, and infection, which were reported to alter visfatin level. Fasting
            blood samples were taken for visfatin, TSH, free thyroxine (FT4), free triiodothyronine
            (FT3), antithyroperoxidase antibodies (TPOAb), antithyroglobulin antibodies (TgAb),
            glucose, and insulin levels. The highest visfatin serum concentration was in AIT group,
            and healthy controls had visfatin level higher than TT (
            <i>p</i> = 0.0001). Simple linear regression analysis revealed that visfatin serum concentration
            was significantly associated with autoimmunity (
            <i>β</i> = 0.1014; 
            <i>p</i> = 0.003), FT4 (
            <i>β</i> = 0.05412; 
            <i>p</i> = 0.048), FT3 (
            <i>β</i> = 0.05242; 
            <i>p</i> = 0.038), and TPOAb (
            <i>β</i> = 0.0002; 
            <i>p</i> = 0.0025), and the relationships were further confirmed in the multivariate regression
            analysis.
         </p>
      </div>
      <div tagxxx="sec">
         <title>1. Introduction</title>
         <p>Visfatin, also known as nicotinamide phosphoribosyltransferase (NAMPT) as well as
            pre-B-cell colony-enhancing factor, is a multifaceted protein with suggested enzymatic,
            immunological, and metabolic properties. Visfatin has been analyzed in hypo- and hyperthyroidism
            in
            <i> in vitro</i> and
            <i> in vivo</i> studies, but results are inconclusive [
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>]. In addition, NAMPT level was found to be elevated in many autoimmune diseases,
            that is, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases,
            and psoriasis [
            <span ref-type="bibr" rid="B2">
               <sup>
                  <a href="#B2">2</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>]. Visfatin also positively correlates with activity and severity of rheumatoid arthritis
            and psoriasis [
            <span ref-type="bibr" rid="B2">
               <sup>
                  <a href="#B2">2</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>]. We have recently found an overexpression of NAMPT in leukocytes of patients with
            Graves' ophthalmopathy with corresponding increased serum concentration (accepted
            manuscript). Our findings suggest that visfatin might be involved in autoimmune processes
            in thyroid diseases.
         </p>
         <p>In our opinion, the controversial findings of visfatin in thyroid hormone deficiency
            may arise from the heterogeneity of thyroid dysfunction. We hypothesized that regulation
            of visfatin in hypothyroidism might be altered by coexisting chronic autoimmune thyroiditis,
            since high visfatin levels were observed in other autoimmune diseases. To answer the
            question about the influence of coexisting chronic autoimmune inflammation on visfatin
            level, we analyzed its serum concentration among hypothyroid patients with chronic
            autoimmune thyroiditis and in patients after thyroidectomy, who were negative for
            thyroid antibodies.
         </p>
      </div>
      <div tagxxx="sec">
         <title>2. Patients and Methods</title>
         <div tagxxx="sec">
            <h3>2.1. Study Design and Patient Recruitment</h3>
            <p>This is a prospective case-control study of 118 subjects. The autoimmune study group
               (AIT) consisted of 39 patients newly diagnosed with hypothyroidism in a course of
               chronic autoimmune thyroiditis. The nonautoimmune study group (TT) consisted of 40
               patients thyroidectomized due to the differentiated thyroid cancer staged pT1. TT
               patients were evaluated five years after radioiodine remnant ablation and were negative
               for thyroglobulin and radioiodine uptake in a whole body scintigraphy (WBS). They
               achieved endogenous TSH stimulation and became hypothyroid after L-T4 withdrawal for
               at least 4 weeks. The control group comprised 39 healthy volunteers adjusted for age,
               sex, and BMI with normal thyroid function and negative thyroid antibodies. Exclusion
               criteria consisted of other autoimmune diseases, active neoplastic disease, diabetes
               mellitus, and infection, which were reported to alter visfatin level. Every patient
               underwent physical examination and thyroid/neck ultrasound examination.
            </p>
         </div>
         <div tagxxx="sec">
            <h3>2.2. Laboratory Analysis</h3>
            <p>Fasting blood samples were taken for visfatin, TSH, free thyroxine (FT4), free triiodothyronine
               (FT3), antithyroperoxidase antibodies (TPOAb), antithyroglobulin antibodies (TgAb),
               glucose, and insulin levels. In TT group also thyroglobulin (Tg) level was measured.
            </p>
            <p>Visfatin serum concentration was measured with ELISA Assay Kit from Phoenix Pharmaceuticals.
               TSH, FT4, and FT3 were measured using the electrochemiluminescence technique in Cobas
               E 601 (norm ranges: TSH 0.27–4.2 mU/L; FT4 11.5–21.0 pmol/L; FT3 3.93–7.70 pmol/L).
               TPOAb and TgAb were measured by radioimmunoassay (norm range: &lt;34 IU/mL and &lt;115 IU/mL,
               resp.). Glucose level was assessed with the use of Hitachi Cobas e601 chemiluminescent
               analyzer (Roche Diagnostics) and insulin concentration was assessed using ELISA kit
               from Phoenix Pharmaceuticals. The estimate of insulin resistance by homeostasis model
               assessment (HOMA-IR) was calculated.
            </p>
            <p>The study was approved by the local ethics committee, and informed consent was signed
               by every subject.
            </p>
         </div>
         <div tagxxx="sec">
            <h3>2.3. Statistical Analysis</h3>
            <p>Statistical analysis was performed with MedCalc version 12.1.3.0 (MedCalc Software,
               Mariakerke, Belgium). Normality was analyzed by D'Agostino-Pearson test. Variables
               with normal distribution were compared between three groups with one-way analysis
               of variance. If data did not follow normal distribution, comparison of the analyzed
               parameters between three groups was performed with the Kruskal-Wallis test. Simple
               regression analysis was used to test for the relationships between them. Before inclusion
               to this statistical analysis, nonnormally distributed parameters were logarithmically
               transformed. Furthermore, stepwise multiple regression analysis was employed to investigate
               the influence of various parameters on visfatin serum concentration [age, BMI, FT3,
               autoimmunity (yes/no), HOMA-IR]. Variables were entered into the model if their associated
               
               <i>p</i>-values were less than 0.05 and then sequentially removed if their associated 
               <i>p</i>-values became greater than 0.2. Tests were considered to be statistically significant
               if 
               <i>p</i>-value was lower than 0.05.
            </p>
         </div>
      </div>
      <div tagxxx="sec">
         <title>3. Results</title>
         <p>Clinical and laboratory data of the study groups and the control group are shown in
            
            <span ref-type="table" rid="tab1">
               <a href="#tab1">Table 1</a>
            </span>.
         </p>
         <p>The highest visfatin serum concentration was in AIT group, and healthy controls had
            visfatin level higher than TT (
            <i>p</i> = 0.0001) (
            <span ref-type="fig" rid="fig1">Figure 1</span>). Three groups did not differ in age, sex, BMI, fasting glucose, and insulin levels,
            HOMA-IR. They had statistically different TSH, FT4, FT3, and TgAb levels (
            <span ref-type="table" rid="tab1">
               <a href="#tab1">Table 1</a>
            </span>). AIT group had higher TPOAb level. TT and controls were negative for TPOAb and TgAb.
         </p>
         <p>Simple linear regression analysis revealed that visfatin serum concentration was significantly
            associated with autoimmunity (
            <i>β</i> = 0.1014; 
            <i>p</i> = 0.003), FT4 (
            <i>β</i> = 0.05412; 
            <i>p</i> = 0.048), FT3 (
            <i>β</i> = 0.05242; 
            <i>p</i> = 0.038), and TPOAb (
            <i>β</i> = 0.0002; 
            <i>p</i> = 0.0025) (
            <span ref-type="fig" rid="fig2">Figure 2</span>). There was no association between visfatin and age, sex, BMI, TSH, TgAb, fasting
            insulin and glucose levels, and HOMA-IR (
            <span ref-type="table" rid="tab2">
               <a href="#tab2">Table 2</a>
            </span>).
         </p>
         <p>In the stepwise multiple regression analysis we confirmed the association between
            serum visfatin level and autoimmunity (coefficient = 3.8461; 
            <i>p</i> = 0.0001), and FT3 (coefficient = 0.4198; 
            <i>p</i> = 0.0441), whereas age, BMI, and HOMA-IR did not contribute significantly. In separate
            stepwise multiple regression analysis we confirmed the association of serum visfatin
            concentration with autoimmunity (coefficient = 4.1105; 
            <i>p</i> = 0.0001) and FT4 (coefficient = 0.1397; 
            <i>p</i> = 0.038), whereas age, BMI, and HOMA-IR did not enter the model. Similarly, association
            of visfatin with TPOAb (coefficient = 0.0057; 
            <i>p</i> = 0.0163) was observed with adjustment for age, BMI, FT3, and HOMA-IR in multivariate
            regression analysis.
         </p>
      </div>
      <div tagxxx="sec">
         <title>4. Discussion</title>
         <p>To date, visfatin serum concentration in hypothyroidism has been analyzed in a few
            studies [
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>]. Caixàs et al. reported elevated level of this adipocytokine in hypothyroidism with
            further increase after restoration of thyroid function [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>]. Ozkaya et al. observed that visfatin level decreased after recovery [
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>]. In those articles the etiology of hypothyroidism varied from chronic autoimmune
            thyroiditis, postpartum thyroiditis to thyroid function insufficiency after radioiodine
            treatment or after thyroidectomy. Hence, to date autoimmune status of studied patients
            has not been taken into consideration. We hypothesized that these controversial findings
            might result from heterogeneity of study groups.
         </p>
         <p>To answer the question, whether coexisting autoimmune inflammation influences visfatin
            level in hypothyroid patients, we analyzed its serum concentration in chronic autoimmune
            thyroiditis and thyroidectomized patients negative for thyroid antibodies. Since we
            have previously proved that visfatin mRNA expression is increased in thyroid malignancies
            and is correlated with tumor stage, we recruited only those patients who did not have
            any features of active neoplastic disease [
            <span ref-type="bibr" rid="B8">
               <sup>
                  <a href="#B8">8</a>
               </sup>
            </span>]. We also recruited the control group adjusted for age, sex, and BMI. To the best
            of our knowledge, this is the first study addressing the changes in the release of
            visfatin in thyroid autoimmunity. We came to interesting results indicating that visfatin
            serum concentration in hypothyroid patients is associated with both autoimmunity and
            free thyroid hormones level (FT4, FT3). We confirmed our findings in adjusted models.
         </p>
         <p>Visfatin has been recognized as a cytokine with a broad range of immune and inflammatory
            activities, including induction of inflammatory cytokines, and regulation of macrophage
            and lymphocyte proliferation [
            <span ref-type="bibr" rid="B9">
               <sup>
                  <a href="#B9">9</a>
               </sup>
            </span>]. Visfatin stimulates the production of proinflammatory cytokines (IL-6, TNF-
            <i>α</i>, and IL-1
            <i>β</i>) and potentially acts as a chemotactic factor for monocytes. Furthermore, its expression
            is upregulated by IL-6, TNF-
            <i>α</i>, and IL-1
            <i>β</i> [
            <span ref-type="bibr" rid="B10">
               <sup>
                  <a href="#B10">10</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B12">
               <sup>
                  <a href="#B12">12</a>
               </sup>
            </span>]. Enhanced mRNA expression of visfatin was observed in inflamed mucosa of patients
            with inflammatory bowel disease (IBD) [
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>]. Further analysis identified that antigen presenting cells (i.e., macrophages, dendritic
            cells) might be a main source of this protein in IBD. Visfatin has also potency for
            activation of T cells by upregulation of costimulatory molecules (CD40, CD54, and
            CD80) on monocytes. We observed the positive association between visfatin and TPOAb,
            and the latter is considered the best serological marker of chronic autoimmune thyroiditis.
            Furthermore, TPOAb contribute to thyroid destruction through antibody- and complement-dependent
            cell-cytotoxicity [
            <span ref-type="bibr" rid="B13">
               <sup>
                  <a href="#B13">13</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B14">
               <sup>
                  <a href="#B14">14</a>
               </sup>
            </span>]. The first mechanism is associated with mononuclear cell infiltration of thyroid
            stroma. In addition, Th1-derived cytokines (Il-2, TNF-
            <i>α</i>, and INF) were found to be elevated in patients with chronic autoimmune thyroiditis
            [
            <span ref-type="bibr" rid="B15">
               <sup>
                  <a href="#B15">15</a>
               </sup>
            </span>]. Also, Il-1
            <i>β</i> and TNF-
            <i>α</i> have been recently reported to discriminate chronic autoimmune hypothyroid children
            from healthy controls [
            <span ref-type="bibr" rid="B16">
               <sup>
                  <a href="#B16">16</a>
               </sup>
            </span>]. Altogether, association of visfatin with TPOAb observed in our study further supports
            our hypothesis that visfatin might be involved in the pathogenesis of chronic autoimmune
            thyroiditis.
         </p>
         <p>We also reported that visfatin serum concentration depends on FT3 and FT4. Our findings
            about the association of visfatin with FT3 levels are in accordance with the results
            of
            <i> in vitro</i> and
            <i> in vivo</i> studies. However, controversial results whether T3 stimulates or downregulates the
            production of visfatin were found. Ozkaya et al. showed the significant negative correlation
            between visfatin and FT3 [
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>]. In contrast, Caixàs et al. did not find any relationship between visfatin and free
            thyroid hormones [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>].
            <i> In vitro</i> experiment showed the nonlinear regulation of visfatin mRNA expression in the 3T3-L1
            cell culture model affected by T3 [
            <span ref-type="bibr" rid="B17">
               <sup>
                  <a href="#B17">17</a>
               </sup>
            </span>]. Since our study groups significantly differed with free thyroid hormones levels,
            we were able to analyze visfatin concentration in a broad spectrum of FT3 and FT4.
            Therefore, we might suggest that pattern of visfatin changes varies in different FT3
            concentration.
         </p>
         <p>According to our observations, as well as other authors, visfatin did not reflect
            insulin resistance assessed by HOMA-IR [
            <span ref-type="bibr" rid="B18">
               <sup>
                  <a href="#B18">18</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B19">
               <sup>
                  <a href="#B19">19</a>
               </sup>
            </span>]. Although, there are studies confirming this relationship [
            <span ref-type="bibr" rid="B20">
               <sup>
                  <a href="#B20">20</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B21">
               <sup>
                  <a href="#B21">21</a>
               </sup>
            </span>]. The metabolic role of visfatin remains unclear.
         </p>
         <p>Our study might then prove that visfatin in hypothyroidism depends on thyroid hormones
            level and coexisting autoimmunity. We may assume that these two factors should be
            taken into consideration to assess visfatin level in patients with thyroid dysfunction.
            In addition, the possible involvement of visfatin in pathogenesis of chronic autoimmune
            thyroiditis needs further research.
         </p>
      </div>
      <div tagxxx="sec">
         <title>Limitation of the Study</title>
         <p>The main limitation of our study is its cross-sectional design that does not enable
            us to reveal the causal pathways of relationship between visfatin and autoimmune thyroiditis.
            However, we used very strict criteria of exclusion to limit the possible influence
            of other known factors such as diabetes mellitus, other autoimmune processes, infection,
            and active neoplastic disease. Our nonautoimmune group with hypothyroidism had been
            thyroidectomized at least 5 years earlier and did not have any clinical nor laboratory
            features of active thyroid cancer.
         </p>
      </div>
      <back>
         <div tagxxx="ack">
            <title>Acknowledgments</title>
            <p>The authors thank Elżbieta Wrotkowska for her expert technical assistance. This study
               was funded by Poznan University Grant for Young Scientists (502-14-02221355-10212
               and 502-14-02221355-99664) and the National Science Centre in Poland Grant no. DEC-2012/07/N/NZ5/01736.
               The study was also supported by Polpharma Scientific Foundation.
            </p>
         </div>
         <div tagxxx="sec">
            <title>Conflict of Interests</title>
            <p>The authors declare that there is no conflict of interest regarding the publication
               of this paper.
            </p>
         </div>
         <div tag="ref-list">
            <ul>
               <li tag="ref">
                  <a name="B1"></a>
                  <label>1</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Cinar</span>
                           <span tagx="given-names">N.</span>
                        </name>
                        <name>
                           <span tagx="surname">Gurlek</span>
                           <span tagx="given-names">A.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid:
                        an experimental and clinical update
                     </span>
                     <span tagx="source">
                        <i>Endocrine Connections</i>
                     </span>
                     <span tagx="year">2013</span>
                     <span tagx="volume">2</span>
                     <div tagxxx="issue">4</div>
                     <span tagx="fpage">R30</span>
                     <span tagx="lpage">R38</span>
                     <span class="pub-id'">[10.1530/ec-13-0061]</span>
                     <span class="pub-id'">[24145612]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B2"></a>
                  <label>2</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Brentano</span>
                           <span tagx="given-names">F.</span>
                        </name>
                        <name>
                           <span tagx="surname">Schorr</span>
                           <span tagx="given-names">O.</span>
                        </name>
                        <name>
                           <span tagx="surname">Ospelt</span>
                           <span tagx="given-names">C.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid
                        arthritis with proinflammatory and matrix-degrading activities
                     </span>
                     <span tagx="source">
                        <i>Arthritis &amp; Rheumatism</i>
                     </span>
                     <span tagx="year">2007</span>
                     <span tagx="volume">56</span>
                     <div tagxxx="issue">9</div>
                     <span tagx="fpage">2829</span>
                     <span tagx="lpage">2839</span>
                     <span class="pub-id'">[10.1002/art.22833]</span>
                     <span class="pub-id'">[2-s2.0-34848847894]</span>
                     <span class="pub-id'">[17763446]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B3"></a>
                  <label>3</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Chung</span>
                           <span tagx="given-names">C. P.</span>
                        </name>
                        <name>
                           <span tagx="surname">Long</span>
                           <span tagx="given-names">A. G.</span>
                        </name>
                        <name>
                           <span tagx="surname">Solus</span>
                           <span tagx="given-names">J. F.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin
                        resistance and coronary atherosclerosis
                     </span>
                     <span tagx="source">
                        <i>Lupus</i>
                     </span>
                     <span tagx="year">2009</span>
                     <span tagx="volume">18</span>
                     <div tagxxx="issue">9</div>
                     <span tagx="fpage">799</span>
                     <span tagx="lpage">806</span>
                     <span class="pub-id'">[10.1177/0961203309103582]</span>
                     <span class="pub-id'">[2-s2.0-67650644583]</span>
                     <span class="pub-id'">[19578104]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B4"></a>
                  <label>4</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Moschen</span>
                           <span tagx="given-names">A. R.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kaser</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Enrich</span>
                           <span tagx="given-names">B.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Visfatin, an adipocytokine with proinflammatory and immunomodulating properties</span>
                     <span tagx="source">
                        <i>The Journal of Immunology</i>
                     </span>
                     <span tagx="year">2007</span>
                     <span tagx="volume">178</span>
                     <div tagxxx="issue">3</div>
                     <span tagx="fpage">1748</span>
                     <span tagx="lpage">1758</span>
                     <span class="pub-id'">[10.4049/jimmunol.178.3.1748]</span>
                     <span class="pub-id'">[2-s2.0-33846527541]</span>
                     <span class="pub-id'">[17237424]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B5"></a>
                  <label>5</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Ismail</span>
                           <span tagx="given-names">S. A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Mohamed</span>
                           <span tagx="given-names">S. A.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation
                        to disease severity
                     </span>
                     <span tagx="source">
                        <i>British Journal of Dermatology</i>
                     </span>
                     <span tagx="year">2012</span>
                     <span tagx="volume">167</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">436</span>
                     <span tagx="lpage">439</span>
                     <span class="pub-id'">[10.1111/j.1365-2133.2012.10980.x]</span>
                     <span class="pub-id'">[2-s2.0-84864397953]</span>
                     <span class="pub-id'">[22486212]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B6"></a>
                  <label>6</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Caixàs</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Tirado</span>
                           <span tagx="given-names">R.</span>
                        </name>
                        <name>
                           <span tagx="surname">Vendrell</span>
                           <span tagx="given-names">J.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after
                        normalization of thyroid function and are not related to insulin resistance, anthropometric
                        or inflammatory parameters
                     </span>
                     <span tagx="source">
                        <i>Clinical Endocrinology</i>
                     </span>
                     <span tagx="year">2009</span>
                     <span tagx="volume">71</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">733</span>
                     <span tagx="lpage">738</span>
                     <span class="pub-id'">[10.1111/j.1365-2265.2009.03546.x]</span>
                     <span class="pub-id'">[2-s2.0-70349678940]</span>
                     <span class="pub-id'">[19222486]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B7"></a>
                  <label>7</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Ozkaya</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Sahin</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Cakal</span>
                           <span tagx="given-names">E.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism
                        before and after control of thyroid function
                     </span>
                     <span tagx="source">
                        <i>Journal of Endocrinological Investigation</i>
                     </span>
                     <span tagx="year">2009</span>
                     <span tagx="volume">32</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">435</span>
                     <span tagx="lpage">439</span>
                     <span class="pub-id'">[10.3275/6296]</span>
                     <span class="pub-id'">[2-s2.0-70350336255]</span>
                     <span class="pub-id'">[19498324]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B8"></a>
                  <label>8</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Sawicka-Gutaj</span>
                           <span tagx="given-names">N.</span>
                        </name>
                        <name>
                           <span tagx="surname">Waligórska-Stachura</span>
                           <span tagx="given-names">J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Andrusiewicz</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and
                        its correlation with tumor stage and with survivin/survivin DEx3 expression
                     </span>
                     <span tagx="source">
                        <i>Tumor Biology</i>
                     </span>
                     <span tagx="year">2015</span>
                     <span tagx="volume">36</span>
                     <div tagxxx="issue">10</div>
                     <span tagx="fpage">7859</span>
                     <span tagx="lpage">7863</span>
                     <span class="pub-id'">[10.1007/s13277-015-3506-z]</span>
                     <span class="pub-id'">[25946974]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B9"></a>
                  <label>9</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Luk</span>
                           <span tagx="given-names">T.</span>
                        </name>
                        <name>
                           <span tagx="surname">Malam</span>
                           <span tagx="given-names">Z.</span>
                        </name>
                        <name>
                           <span tagx="surname">Marshall</span>
                           <span tagx="given-names">J. C.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity</span>
                     <span tagx="source">
                        <i>Journal of Leukocyte Biology</i>
                     </span>
                     <span tagx="year">2008</span>
                     <span tagx="volume">83</span>
                     <div tagxxx="issue">4</div>
                     <span tagx="fpage">804</span>
                     <span tagx="lpage">816</span>
                     <span class="pub-id'">[10.1189/jlb.0807581]</span>
                     <span class="pub-id'">[18252866]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B10"></a>
                  <label>10</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Dahl</span>
                           <span tagx="given-names">T. B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Yndestad</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Skjelland</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Increased expression of visfatin in macrophages of human unstable carotid and coronary
                        atherosclerosis: possible role in inflammation and plaque destabilization
                     </span>
                     <span tagx="source">
                        <i>Circulation</i>
                     </span>
                     <span tagx="year">2007</span>
                     <span tagx="volume">115</span>
                     <div tagxxx="issue">8</div>
                     <span tagx="fpage">972</span>
                     <span tagx="lpage">980</span>
                     <span class="pub-id'">[10.1161/circulationaha.106.665893]</span>
                     <span class="pub-id'">[2-s2.0-33847279330]</span>
                     <span class="pub-id'">[17283255]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B11"></a>
                  <label>11</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Ognjanovic</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Bao</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Yamamoto</span>
                           <span tagx="given-names">S. Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Garibay-Tupas</span>
                           <span tagx="given-names">J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Samal</span>
                           <span tagx="given-names">B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Bryant-Greenwood</span>
                           <span tagx="given-names">G. D.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Genomic organization of the gene coding for human pre-B-cell colony enhancing factor
                        and expression in human fetal membranes
                     </span>
                     <span tagx="source">
                        <i>Journal of Molecular Endocrinology</i>
                     </span>
                     <span tagx="year">2001</span>
                     <span tagx="volume">26</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">107</span>
                     <span tagx="lpage">117</span>
                     <span class="pub-id'">[10.1677/jme.0.0260107]</span>
                     <span class="pub-id'">[2-s2.0-0035062540]</span>
                     <span class="pub-id'">[11241162]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B12"></a>
                  <label>12</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Jia</span>
                           <span tagx="given-names">S. H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Li</span>
                           <span tagx="given-names">Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Parodo</span>
                           <span tagx="given-names">J.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation
                        and clinical sepsis
                     </span>
                     <span tagx="source">
                        <i>Journal of Clinical Investigation</i>
                     </span>
                     <span tagx="year">2004</span>
                     <span tagx="volume">113</span>
                     <div tagxxx="issue">9</div>
                     <span tagx="fpage">1318</span>
                     <span tagx="lpage">1327</span>
                     <span class="pub-id'">[10.1172/JCI200419930]</span>
                     <span class="pub-id'">[2-s2.0-2342650912]</span>
                     <span class="pub-id'">[15124023]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B13"></a>
                  <label>13</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Rebuffat</span>
                           <span tagx="given-names">S. A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Nguyen</span>
                           <span tagx="given-names">B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Robert</span>
                           <span tagx="given-names">B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Castex</span>
                           <span tagx="given-names">F.</span>
                        </name>
                        <name>
                           <span tagx="surname">Peraldi-Roux</span>
                           <span tagx="given-names">S.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Antithyroperoxidase antibody-dependent cytotoxicity in autoimmune thyroid disease</span>
                     <span tagx="source">
                        <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>
                     </span>
                     <span tagx="year">2008</span>
                     <span tagx="volume">93</span>
                     <div tagxxx="issue">3</div>
                     <span tagx="fpage">929</span>
                     <span tagx="lpage">934</span>
                     <span class="pub-id'">[10.1210/jc.2007-2042]</span>
                     <span class="pub-id'">[2-s2.0-40849116190]</span>
                     <span class="pub-id'">[18073303]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B14"></a>
                  <label>14</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Ehlers</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Thiel</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Bernecker</span>
                           <span tagx="given-names">C.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific
                        cellular immunity in hashimoto's thyroiditis
                     </span>
                     <span tagx="source">
                        <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>
                     </span>
                     <span tagx="year">2012</span>
                     <span tagx="volume">97</span>
                     <div tagxxx="issue">4</div>
                     <span tagx="fpage">1347</span>
                     <span tagx="lpage">1354</span>
                     <span class="pub-id'">[10.1210/jc.2011-2178]</span>
                     <span class="pub-id'">[2-s2.0-84859540261]</span>
                     <span class="pub-id'">[22259066]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B15"></a>
                  <label>15</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Drugarin</span>
                           <span tagx="given-names">D.</span>
                        </name>
                        <name>
                           <span tagx="surname">Negru</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Koreck</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zosin</span>
                           <span tagx="given-names">I.</span>
                        </name>
                        <name>
                           <span tagx="surname">Cristea</span>
                           <span tagx="given-names">C.</span>
                        </name>
                     </span>
                     <span tagx="article-title">The pattern of a T(H)1 cytokine in autoimmune thyroiditis</span>
                     <span tagx="source">
                        <i>Immunology Letters</i>
                     </span>
                     <span tagx="year">2000</span>
                     <span tagx="volume">71</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">73</span>
                     <span tagx="lpage">77</span>
                     <span class="pub-id'">[10.1016/S0165-2478(99)00156-X]</span>
                     <span class="pub-id'">[2-s2.0-0034141233]</span>
                     <span class="pub-id'">[10714432]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B16"></a>
                  <label>16</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Mikos</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Mikos</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Rabska-Pietrzak</span>
                           <span tagx="given-names">B.</span>
                        </name>
                        <name>
                           <span tagx="surname">Niedziela</span>
                           <span tagx="given-names">M.</span>
                        </name>
                     </span>
                     <span tagx="article-title">The clinical role of serum concentrations of selected cytokines: IL-1
                        <i>β</i>, TNF-
                        <i>α</i> and IL-6 in diagnosis of autoimmune thyroid disease (AITD) in children
                     </span>
                     <span tagx="source">
                        <i>Autoimmunity</i>
                     </span>
                     <span tagx="year">2014</span>
                     <span tagx="volume">47</span>
                     <div tagxxx="issue">7</div>
                     <span tagx="fpage">466</span>
                     <span tagx="lpage">472</span>
                     <span class="pub-id'">[10.3109/08916934.2014.914175]</span>
                     <span class="pub-id'">[2-s2.0-84912026483]</span>
                     <span class="pub-id'">[24801540]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B17"></a>
                  <label>17</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Han</span>
                           <span tagx="given-names">J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">T.-O.</span>
                        </name>
                        <name>
                           <span tagx="surname">Xiao</span>
                           <span tagx="given-names">W.-H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Chang</span>
                           <span tagx="given-names">C.-Q.</span>
                        </name>
                        <name>
                           <span tagx="surname">Ai</span>
                           <span tagx="given-names">H.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism
                        is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine
                        with various concentrations
                     </span>
                     <span tagx="source">
                        <i>Chinese Medical Journal</i>
                     </span>
                     <span tagx="year">2012</span>
                     <span tagx="volume">125</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">874</span>
                     <span tagx="lpage">881</span>
                     <span class="pub-id'">[10.3760/cma.j.issn.0366-6999.2012.05.026]</span>
                     <span class="pub-id'">[2-s2.0-84863347225]</span>
                     <span class="pub-id'">[22490590]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B18"></a>
                  <label>18</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Oki</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Yamane</span>
                           <span tagx="given-names">K.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kamei</span>
                           <span tagx="given-names">N.</span>
                        </name>
                        <name>
                           <span tagx="surname">Nojima</span>
                           <span tagx="given-names">H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kohno</span>
                           <span tagx="given-names">N.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Circulating visfatin level is correlated with inflammation, but not with insulin resistance</span>
                     <span tagx="source">
                        <i>Clinical Endocrinology</i>
                     </span>
                     <span tagx="year">2007</span>
                     <span tagx="volume">67</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">796</span>
                     <span tagx="lpage">800</span>
                     <span class="pub-id'">[10.1111/j.1365-2265.2007.02966.x]</span>
                     <span class="pub-id'">[2-s2.0-35448980420]</span>
                     <span class="pub-id'">[17634078]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B19"></a>
                  <label>19</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Pagano</span>
                           <span tagx="given-names">C.</span>
                        </name>
                        <name>
                           <span tagx="surname">Pilon</span>
                           <span tagx="given-names">C.</span>
                        </name>
                        <name>
                           <span tagx="surname">Olivieri</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related
                        to insulin resistance in humans
                     </span>
                     <span tagx="source">
                        <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>
                     </span>
                     <span tagx="year">2006</span>
                     <span tagx="volume">91</span>
                     <div tagxxx="issue">8</div>
                     <span tagx="fpage">3165</span>
                     <span tagx="lpage">3170</span>
                     <span class="pub-id'">[10.1210/jc.2006-0361]</span>
                     <span class="pub-id'">[2-s2.0-33747745349]</span>
                     <span class="pub-id'">[16720654]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B20"></a>
                  <label>20</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Chang</span>
                           <span tagx="given-names">Y.-H.</span>
                        </name>
                        <name>
                           <span tagx="surname">Chang</span>
                           <span tagx="given-names">D.-M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Lin</span>
                           <span tagx="given-names">K.-C.</span>
                        </name>
                        <name>
                           <span tagx="surname">Shin</span>
                           <span tagx="given-names">S.-J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Lee</span>
                           <span tagx="given-names">Y.-J.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic
                        syndrome and cardiovascular diseases: a meta-analysis and systemic review
                     </span>
                     <span tagx="source">
                        <i>Diabetes/Metabolism Research and Reviews</i>
                     </span>
                     <span tagx="year">2011</span>
                     <span tagx="volume">27</span>
                     <div tagxxx="issue">6</div>
                     <span tagx="fpage">515</span>
                     <span tagx="lpage">527</span>
                     <span class="pub-id'">[10.1002/dmrr.1201]</span>
                     <span class="pub-id'">[2-s2.0-80052583612]</span>
                     <span class="pub-id'">[21484978]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B21"></a>
                  <label>21</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Kowalska</span>
                           <span tagx="given-names">I.</span>
                        </name>
                        <name>
                           <span tagx="surname">Straczkowski</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Nikolajuk</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in
                        lean and obese women with polycystic ovary syndrome
                     </span>
                     <span tagx="source">
                        <i>Human Reproduction</i>
                     </span>
                     <span tagx="year">2007</span>
                     <span tagx="volume">22</span>
                     <div tagxxx="issue">7</div>
                     <span tagx="fpage">1824</span>
                     <span tagx="lpage">1829</span>
                     <span class="pub-id'">[10.1093/humrep/dem118]</span>
                     <span class="pub-id'">[2-s2.0-34447336403]</span>
                     <span class="pub-id'">[17582143]</span>
                  </span>
               </li>
            </ul>
         </div>
      </back>
      <div tagxxx="floats-group">
         <fig>
            <label>Figure 1</label>
            <caption>
               <p>Comparison of visfatin serum concentration in hypothyroid patients with chronic autoimmune
                  thyroiditis (AIT), in hypothyroid patients after total thyroidectomy (TT), and in
                  healthy controls (controls). Central box represents the values from the lower to upper
                  quartile (25th to 75th percentile). The middle line represents the median. The thin
                  vertical lines extending up or down from the boxes to horizontal lines (so-called
                  whiskers) extend to a multiple of 1.5 × the distance of the upper and lower quartile,
                  respectively.
               </p>
            </caption>
            <graphic></graphic>
         </fig>
         <fig>
            <label>Figure 2</label>
            <caption>
               <p>Association between visfatin serum level and FT3 (a), FT4 (b), and TPOAb (c). Data
                  were log-transformed to achieve normal distribution.
               </p>
            </caption>
            <graphic></graphic>
         </fig>
         <div id="tab1">
            <label>Table 1</label>
            <caption>
               <p>Comparison of clinical and laboratory characteristics between the study groups and
                  controls.
               </p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th> </th>
                     <th>Autoimmune hypothyroidism
                        <div tagxxx="break"></div>(
                        <i>n</i> = 39)
                     </th>
                     <th>Nonautoimmune hypothyroidism
                        <div tagxxx="break"></div>(
                        <i>n</i> = 40)
                     </th>
                     <th>Controls
                        <div tagxxx="break"></div>(
                        <i>n</i> = 39)
                     </th>
                     <th>
                        <i>p</i>
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Sex (F—females; 
                        <div tagxxx="break"></div>M—males)
                     </td>
                     <td>F 34
                        <div tagxxx="break"></div>M 5
                     </td>
                     <td>F 37
                        <div tagxxx="break"></div>M 3
                     </td>
                     <td>F 34
                        <div tagxxx="break"></div>M 5
                     </td>
                     <td>0.5420</td>
                  </tr>
                  <tr>
                     <td>Age [yr] median (IQR)</td>
                     <td>46 (34.5–54)</td>
                     <td>41.5 (29.5–48)</td>
                     <td>43 (36.3–54)</td>
                     <td>0.1837</td>
                  </tr>
                  <tr>
                     <td>BMI [kg/m
                        <sup>2</sup>] 
                        <div tagxxx="break"></div>median (IQR)
                     </td>
                     <td>23.4 (21.65–25.4)</td>
                     <td>25.4 (21.55–27.15)</td>
                     <td>23.3 (20.73–26.13)</td>
                     <td>0.2704</td>
                  </tr>
                  <tr>
                     <td>Glucose [mg/dL] mean (SD)</td>
                     <td>93 (9.7)</td>
                     <td>90.8 (9.6)</td>
                     <td>90.0 (8.0)</td>
                     <td>0.319</td>
                  </tr>
                  <tr>
                     <td>Insulin [
                        <i>μ</i>U/mL] mean (SD)
                     </td>
                     <td>7.7 (3.4)</td>
                     <td>8.14 (3.12)</td>
                     <td>8.99 (3.2)</td>
                     <td>0.202</td>
                  </tr>
                  <tr>
                     <td>HOMA-IR 
                        <div tagxxx="break"></div>mean (SD)
                     </td>
                     <td>1.77 (0.77)</td>
                     <td>1.82 (0.72)</td>
                     <td>2.02 (0.82)</td>
                     <td>0.316</td>
                  </tr>
                  <tr>
                     <td>TSH [
                        <i>μ</i>U/mL] 
                        <div tagxxx="break"></div>median (IQR)
                     </td>
                     <td>57.3 
                        <div tagxxx="break"></div>(35.4–100)
                     </td>
                     <td>94.5 
                        <div tagxxx="break"></div>(62.13–100)
                     </td>
                     <td>1.8 
                        <div tagxxx="break"></div>(1.38–2.57)
                     </td>
                     <td>
                        <b>&lt;0.0001</b>
                     </td>
                  </tr>
                  <tr>
                     <td>FT4 [pmol/L] 
                        <div tagxxx="break"></div>median (IQR)
                     </td>
                     <td>5.4 
                        <div tagxxx="break"></div>(2.16–8.16)
                     </td>
                     <td>1.84 
                        <div tagxxx="break"></div>(1.34–2.67)
                     </td>
                     <td>15.96 
                        <div tagxxx="break"></div>(14.8–17.39)
                     </td>
                     <td>
                        <b>&lt;0.0001</b>
                     </td>
                  </tr>
                  <tr>
                     <td>FT3 [pmol/L]
                        <div tagxxx="break"></div>mean (SD)
                     </td>
                     <td>2.28 (1.4)</td>
                     <td>0.7 (0.37)</td>
                     <td>5.15 (0.57)</td>
                     <td>
                        <b>&lt;0.001</b>
                     </td>
                  </tr>
                  <tr>
                     <td>TPOAb [IU/mL]
                        <div tagxxx="break"></div>median (IQR)
                     </td>
                     <td>189 
                        <div tagxxx="break"></div>(56.25–574.5)
                     </td>
                     <td>11 
                        <div tagxxx="break"></div>(7–16)
                        <sup>a</sup>
                     </td>
                     <td>9 
                        <div tagxxx="break"></div>(6–12.75)
                        <sup>a</sup>
                     </td>
                     <td>
                        <b>&lt;0.001</b>
                     </td>
                  </tr>
                  <tr>
                     <td>TgAb [IU/mL]
                        <div tagxxx="break"></div>median (IQR)
                     </td>
                     <td>267 (79–504)</td>
                     <td>17 (13–21)</td>
                     <td>10 (10–14)</td>
                     <td>
                        <b>&lt;0.0001</b>
                     </td>
                  </tr>
                  <tr>
                     <td>Tg [ng/mL]
                        <div tagxxx="break"></div>mean (SD)
                     </td>
                     <td>—</td>
                     <td>0.4 (0.34)</td>
                     <td>—</td>
                     <td>—</td>
                  </tr>
                  <tr>
                     <td>Visfatin [ng/mL] median (IQR)</td>
                     <td>10.85 
                        <div tagxxx="break"></div>(9.52–13.03)
                     </td>
                     <td>8.97 
                        <div tagxxx="break"></div>(7.25–10.3)
                     </td>
                     <td>9.54 
                        <div tagxxx="break"></div>(8.68–11.4)
                     </td>
                     <td>
                        <b>0.0001</b>
                     </td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn>
                  <p>
                     <sup>a</sup>Values followed by the same letter do not differ significantly.
                  </p>
               </fn>
               <fn>
                  <p>TPOAb antithyroperoxidase antibodies; TgAb antithyroglobulin antibodies; Tg thyroglobulin.</p>
               </fn>
            </table-wrap-foot>
         </div>
         <div id="tab2">
            <label>Table 2</label>
            <caption>
               <p>Simple linear regression analysis using visfatin serum concentration as dependent
                  variable.
               </p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th>Variable</th>
                     <th>Visfatin serum concentration (log)</th>
                  </tr>
                  <tr>
                     <th>
                        <i>β</i>
                     </th>
                     <th>
                        <i>p</i>
                     </th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Age</td>
                     <td>−0.001</td>
                     <td>0.3325</td>
                  </tr>
                  <tr>
                     <td>Sex</td>
                     <td>−0.0229</td>
                     <td>0.564</td>
                  </tr>
                  <tr>
                     <td>BMI (log)</td>
                     <td>−0.3624</td>
                     <td>0.059</td>
                  </tr>
                  <tr>
                     <td>TSH (log)</td>
                     <td>−0.0046</td>
                     <td>0.784</td>
                  </tr>
                  <tr>
                     <td>FT4 (log)</td>
                     <td>
                        <b>0.05412</b>
                     </td>
                     <td>
                        <b>0.048</b>
                     </td>
                  </tr>
                  <tr>
                     <td>FT3 (log)</td>
                     <td>
                        <b>0.05242</b>
                     </td>
                     <td>
                        <b>0.038</b>
                     </td>
                  </tr>
                  <tr>
                     <td>TPOAb </td>
                     <td>
                        <b>0.0002</b>
                     </td>
                     <td>
                        <b>0.0025</b>
                     </td>
                  </tr>
                  <tr>
                     <td>TgAb</td>
                     <td>0.00001</td>
                     <td>0.515</td>
                  </tr>
                  <tr>
                     <td>Fasting glucose</td>
                     <td>0.0009</td>
                     <td>0.489</td>
                  </tr>
                  <tr>
                     <td>Fasting insulin</td>
                     <td>−0.0026</td>
                     <td>0.518</td>
                  </tr>
                  <tr>
                     <td>HOMA-IR (log)</td>
                     <td>−0.0006</td>
                     <td>0.720</td>
                  </tr>
                  <tr>
                     <td>Autoimmunity (yes/no)</td>
                     <td>
                        <b>0.1014</b>
                     </td>
                     <td>
                        <b>0.0003</b>
                     </td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn>
                  <p>TPOAb antithyroperoxidase antibodies; TgAb antithyroglobulin antibodies.</p>
               </fn>
            </table-wrap-foot>
         </div>
      </div>
   </article>
</html>